Literature DB >> 2807001

Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix.

R D Alvarez1, S J Soong, W K Kinney, G C Reid, M F Schray, K C Podratz, G W Morley, H M Shingleton.   

Abstract

In a retrospective study conducted at the University of Alabama at Birmingham, the University of Michigan, and the Mayo Clinic, 185 patients with previously untreated FIGO stage IB and IIA squamous cell carcinoma of the cervix were found to have nodal metastasis at the time of radical hysterectomy and pelvic lymphadenectomy. Of these patients, 103 received adjuvant pelvic irradiation. Cancer recurred in 76 patients; the median time to recurrence was 3.1 years. The prognostic significance of patient age, clinical stage, lesion diameter, number and location of nodal metastases, and use of adjuvant radiation therapy was determined by multivariate analysis. Only patient age (P = 0.0006), lesion diameter (P less than 0.0001), and number of nodal metastases (P = 0.0004) were noted to be significant factors in determining overall survival. Rates of recurrence were also related to these factors. Employment of these significant variables led to identification of four risk groups. In general, patients with small cervical lesions (diameter less than 1 cm) and no more than two nodes with metastases fell into the low-risk category; those patients with large cervical lesions (diameter greater than 4 cm) and more than two involved nodes fell into the high-risk category. All other patients were categorized into intermediate-risk groups. Ten-year survival was 92% in the low-risk group (n = 13), 70% in the low-intermediate-risk group (n = 66), 56% in the high-intermediate-risk group (n = 66), and 13% in the high-risk group (n = 20). This risk group classification identifies subgroups of early-stage cervical carcinoma patients found to have nodal metastasis at the time of radical hysterectomy that warrant appropriately selected adjuvant therapy.

Entities:  

Mesh:

Year:  1989        PMID: 2807001     DOI: 10.1016/0090-8258(89)90029-2

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  Definitive radiation therapy for invasive carcinoma of the vagina: impact of high-dose rate intracavitary brachytherapy.

Authors:  Tetsuo Nonaka; Yuko Nakayama; Nobutaka Mizoguchi; Ryo Onose; Hisamori Kato; Hiroki Nakayama
Journal:  Int J Clin Oncol       Date:  2012-02-07       Impact factor: 3.402

Review 2.  Hypoxia and anaemia in patients with cancer of the uterine cervix.

Authors:  Francisco José Andreu-Martínez; Julia M Martínez-Mateu
Journal:  Clin Transl Oncol       Date:  2005-09       Impact factor: 3.405

3.  Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer.

Authors:  Nicole D Fleming; Michael Frumovitz; Kathleen M Schmeler; Ricardo dos Reis; Mark F Munsell; Patricia J Eifel; Pamela T Soliman; Alpa M Nick; Shannon N Westin; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2014-11-18       Impact factor: 5.482

Review 4.  Postoperative radiation therapy for carcinoma of the uterine cervix.

Authors:  Takashi Uno; Koichi Isobe; Seiji Yamamoto; Tetsuya Kawata; Hisao Ito
Journal:  Radiat Med       Date:  2006-02

Review 5.  Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.

Authors:  Fani Kokka; Andrew Bryant; Adeola Olaitan; Elly Brockbank; Melanie Powell; David Oram
Journal:  Cochrane Database Syst Rev       Date:  2022-08-22

6.  Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer.

Authors:  Yun-Hyun Cho; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

7.  Comparison of outcomes between squamous cell carcinoma and adenocarcinoma in patients with surgically treated stage I-II cervical cancer.

Authors:  Makoto Yamauchi; Takeshi Fukuda; Takuma Wada; Masaru Kawanishi; Kenji Imai; Yasunori Hashiguchi; Tomoyuki Ichimura; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Mol Clin Oncol       Date:  2014-05-15

8.  External beam boost irradiation for clinically positive pelvic nodes in patients with uterine cervical cancer.

Authors:  Takuro Ariga; Takafumi Toita; Goro Kasuya; Yutaka Nagai; Morihiko Inamine; Wataru Kudaka; Yasumasa Kakinohana; Youichi Aoki; Sadayuki Murayama
Journal:  J Radiat Res       Date:  2013-01-29       Impact factor: 2.724

9.  The influence of number of high risk factors on clinical outcomes in patients with early-stage cervical cancer after radical hysterectomy and adjuvant chemoradiation.

Authors:  Soyi Lim; Seok-Ho Lee; Kwang Beom Lee; Chan-Yong Park
Journal:  Obstet Gynecol Sci       Date:  2016-05-13

10.  Risk model in stage IB1-IIB cervical cancer with positive node after radical hysterectomy.

Authors:  Zhilan Chen; Kecheng Huang; Zhiyong Lu; Song Deng; Jiaqiang Xiong; Jia Huang; Xiong Li; Fangxu Tang; Zhihao Wang; Haiying Sun; Lin Wang; Shasha Zhou; Xiaoli Wang; Yao Jia; Ting Hu; Juan Gui; Dongyi Wan; Ding Ma; Shuang Li; Shixuan Wang
Journal:  Onco Targets Ther       Date:  2016-05-27       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.